Dr. Glen Jeffery

So I had a very significant failure in a clinical trial because we took a whole group of patients who had macular degeneration.

We treated them with red light.

And we treated their part.

More women have macular degeneration than men.

We took their husbands as the control subjects.

And to a first approximation, we got absolutely no effect whatsoever.

This is kind of a point where, you know, people working with Glenn are losing enthusiasm.

But lo and behold, their husbands died.

They didn't have macular degeneration, but their vision was improving enormously, particularly the way in which they could deal with darkness.

So we stomped around over this.

Something was wrong.

And we found that when we look back at it, we found that the

subjects that we were dealing with, the patients, their disease had reached a certain point.

It had gone beyond a certain point.

Now, when that study was replicated by someone who thought about it a bit more than me, an ophthalmologist called Ben Burton in the UK, he got a great result.

he started to get a really good result.

And when you talk to people about red light, and I talk to people, I talk to Parkinson's societies, I talk to various groups, and I talk to the researchers, and there is one thing that's very clear, is that red light can impact on aging, it can impact on disease.

but it can't do it if that disease has really got its teeth into you, right?

So where we need to get into situations is early on in disease.

So we thought very much about one point about rheumatism, you know, rheumatoid arthritis.